Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Helaba in connection with financing of an acquisition in real estate
Mandate

Vinge has advised Helaba in connection with financing of an acquisition in real estate

June 16, 2017 Banking and Finance

TRIUVA Kapitalverwaltungsgesellschaft mbH, Germany’s leading real estate fund manager, has acquired from Slussgården the city property Lammet 17, located right next to Drottninggatan and Kungsgatan.

The property has 6,700 square meters of office and retail space and Fastighetsvärlden estimates that the price amounts to a bit over 450 million SEK. Catella and Foyen have been advisors to Slussgården and JLL, Roschier, King & Spalding, WSP and Rödl & Partner have been advisors to Triuva. Vinge has advised Landesbank Hessen-Thüringen Girozentrale (Helaba) in connection with the financing of the acquisition.

Vinge’s team consisted of Mikael Ståhl, Helena Håkansson, André Isacson and Ludvig Wettergren.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026